// App-Quantinova.ai

1868 : Estimation of Glomerular Filtration Rate With Serum Cystatin C Accurately Discriminates Renal Dysfunction in Liver Transplant Candidates With End-Stage Liver Disease

Researchers

Presenter

  • S. Gonzalez

Principal Investigators

  • J. Trotter

  • H. Szerlip

  • M. Emmett

  • G. Klintmalm

  • B. Fischbach

  • M. Levy

  • A. Chandrakantan

  • A. Yango

  • A. Rajagopal

  • Y. Barri

  • K. Rice

  • M. Saim

  • L. Melton

Medical Centers

  • Hepatology, Baylor Simmons Transplant Institute, Fort Worth, TX

  • Baylor University Medical Center, Dallas, TX

  • Hepatology, Baylor Simmons Transplant Institute, Fort Worth, TX

  • Hepatology, Baylor Simmons Transplant Institute, Fort Worth, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • End-stage liver disease

  • Chronic kidney disease

  • Renal insufficiency

  • Renal disease

Biomarkers

  • Creatinine

  • Cystatin C

Drug/Treatment

  • Glofil-125

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved